Anti-TMEFF2 Antibody

Raised in rabbit against human TMEFF2 and affinity-purified as an unconjugated IgG polyclonal reagent, this Antibodies.com primary antibody is supplied as a 100 µL vial and is validated for Western blot detection of endogenous tomoregulin protein. The antibody recognizes the transmembrane protein with EGF-like and two follistatin-like domains 2 (TMEFF2), a 374-residue type-I transmembrane proteoglycan whose extracellular region contains a single EGF-like module and two follistatin-like domains that selectively bind PDGF-AA. Cross-reactivity with human, mouse, and rat samples enables parallel immunoblotting across standard mammalian models, supporting comparative studies of methylation-associated silencing in xenograft, knockout, and patient-derived tissue backgrounds.

TMEFF2, also annotated HPP1, TPEF, TR-2, TENB2, and CT120.2, is frequently silenced by 5′-CpG promoter hypermethylation in colorectal, gastric, prostate, breast, and glial tumors, and methylated TMEFF2 sequences in circulating DNA have been proposed as an early diagnostic biomarker. Its short cytoplasmic tail couples to integrin and RhoA signaling to modulate prostate cancer cell adhesion and migration, while ADAM17-mediated ectodomain shedding releases a soluble fragment that engages HER4/erbB-4 in gastric cells and enhances ADAM17-driven AβPP processing in neuronal systems. The antibody can be used to probe whole-cell lysates, membrane-enriched fractions, and brain or prostate tissue homogenates.

Store at -20 °C in working aliquots to limit freeze-thaw cycles and preserve antigen-binding titer. The unconjugated format allows pairing with any HRP- or fluorophore-conjugated secondary antibody for chemiluminescent Western blot or downstream immunodetection, giving flexibility across membrane-based and gel-based assay formats.